Abstract
A series of different Schiff bases of isatin 1-20 was synthesized by the condensation of isatin with primary aromatic amines. It was observed that some of these compounds have the potential to inhibit acetylcholinesterase, whereas some others showed specific activity against butyrylcholinesterase, depending upon substitution on the aromatic ring. Compounds 9 and 20 showed weak acetylcholinesterase inhibitory activity having IC50 values 28.3 ± 0.26 and 159 ± 2.9 μM, respectively. Nonetheless, compounds showed a varying degree of activity against butyrylcholinesterase with IC50 values in the range of 2.8 ± 0.07-82.9 ± 2.2 μM. Compounds 5, 2, and 11 showed IC50 values 2.8 ± 0.07, 5.2 ± 0.10, and 8.1 ± 0.30 μM, respectively, Their activity was compared with standard inhibitor galanthamine IC50 = 0.5 ± 0.01 μM for acetylcholinesterase and IC50 = 8.5 ± 0.01 μM for butyrylcholinesterase, respectively. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.
Keywords: Isatin, Schiff bases, Substitution effect, Butyrylcholinesterase inhibition, Galanthamine, Structure-activity relationship, Acetylcholinestrase inhibition, Butyrylcholinesterase, Gal-anthamine, AChE, senile dementia, Alzheimer's dis-ease, BChE, acetylcholine, indoles, triazoles, spiroheterocy-cle, quinolones, CHN analysis, H-NMR, EI MS, IR, UV spectroscopy, spectrometer, MeOH, Enzyme Inhibition Assay, TLC, EtOH
Letters in Drug Design & Discovery
Title: Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase
Volume: 7 Issue: 10
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Nida Ambreen, Nasim Hasan Rama, Farzana Naz, Shahnaz Perveen and Muhammad Iqbal Choudhary
Affiliation:
Keywords: Isatin, Schiff bases, Substitution effect, Butyrylcholinesterase inhibition, Galanthamine, Structure-activity relationship, Acetylcholinestrase inhibition, Butyrylcholinesterase, Gal-anthamine, AChE, senile dementia, Alzheimer's dis-ease, BChE, acetylcholine, indoles, triazoles, spiroheterocy-cle, quinolones, CHN analysis, H-NMR, EI MS, IR, UV spectroscopy, spectrometer, MeOH, Enzyme Inhibition Assay, TLC, EtOH
Abstract: A series of different Schiff bases of isatin 1-20 was synthesized by the condensation of isatin with primary aromatic amines. It was observed that some of these compounds have the potential to inhibit acetylcholinesterase, whereas some others showed specific activity against butyrylcholinesterase, depending upon substitution on the aromatic ring. Compounds 9 and 20 showed weak acetylcholinesterase inhibitory activity having IC50 values 28.3 ± 0.26 and 159 ± 2.9 μM, respectively. Nonetheless, compounds showed a varying degree of activity against butyrylcholinesterase with IC50 values in the range of 2.8 ± 0.07-82.9 ± 2.2 μM. Compounds 5, 2, and 11 showed IC50 values 2.8 ± 0.07, 5.2 ± 0.10, and 8.1 ± 0.30 μM, respectively, Their activity was compared with standard inhibitor galanthamine IC50 = 0.5 ± 0.01 μM for acetylcholinesterase and IC50 = 8.5 ± 0.01 μM for butyrylcholinesterase, respectively. The structures of all the synthesized compounds were confirmed by spectroscopic analysis.
Export Options
About this article
Cite this article as:
Mohammed Khan Khalid, Rasool Mughal Uzma, Ambreen Nida, Hasan Rama Nasim, Naz Farzana, Perveen Shahnaz and Iqbal Choudhary Muhammad, Schiff Bases of Isatin: Inhibitory Potential Towards Acetylcholinesterase and Butyrylcholinesterase, Letters in Drug Design & Discovery 2010; 7 (10) . https://dx.doi.org/10.2174/1570180811007010716
DOI https://dx.doi.org/10.2174/1570180811007010716 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Nitrendipine Nanoliposome for Transdermal Drug Delivery: Preparation, Characterization and Permeation Studies
Drug Delivery Letters Recent Advances in Targeted Therapy for Glioma
Current Medicinal Chemistry Erythropoietin in Cancer: An Update
Current Molecular Medicine Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry Effect of Antenatal Steroids on Haemodynamics in the Normally Grown and Growth Restricted Fetus
Current Pediatric Reviews Isomannide and Derivatives. Chemical and Pharmaceutical Applications
Mini-Reviews in Organic Chemistry Clinical and Molecular Genetic Aspects of Hypertrophic Cardiomyopathy
Current Cardiology Reviews Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters New Steroidal Anti-Inflammatory Antedrugs: 21-Thioalkylether Derivatives of Methyl 16-Prednisolone Carboxylates
Medicinal Chemistry Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design Tachykinins and the Cardiovascular System
Current Drug Targets Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection
Infectious Disorders - Drug Targets Change in Quality of Life of OSAHS Patients with Minimally Invasive Surgery or CPAP Therapy: A 2-year Retrospective, Single-center Parallel-group Study
Current Molecular Medicine Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets The Role of Vitamin D in Atherosclerosis Inflammation Revisited: More a Bystander than a Player?
Current Vascular Pharmacology Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Cortisol Regulation in the Metabolic Syndrome. A Novel Therapeutic Approach
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prevention of Ischemic Stroke: Overview of Traditional Risk Factors
Current Drug Targets